Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Access Bio Inc Issues FY 2013 Outlook Below Analysts' Estimates


Tuesday, 15 Oct 2013 12:18am EDT 

Access Bio Inc announced that it expects its fiscal year 2013 revenue and operating profit to record KRW 46.4 billion and KRW 12.1 billion, respectively. According to I/B/E/S Estimates, analysts on average are expecting the Company to report revenue of KRW 47.20 billion for the fiscal year 2013.